BIAF
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$15.27
+19.48%Year over year
Reported trailing growth
- Revenue
- -23.2%
- EBITDA
- -33.8%
- EBIT
- -23.0%
- EPS
- -30.7%
- Free cash flow
- -48.4%
- Operating cash flow
- -49.4%
Forward estimates
Based on analyst estimates
- Revenue
- -30.1%
- EBITDA
- -37.1%
- EPS
- +51.3%
Three-year CAGR
- Revenue
- +986.6%
- EBITDA
- -71.9%
- EBIT
- -18.1%
- Net income
- -64.9%
- EPS
- +61.5%
- Free cash flow
- -27.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026